The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•10 June 2026•

2 min read

Class Action Lawsuits Filed Against Veritone, GeneDx, and PicS Over Financial Misconduct

Key Facts

1Veritone faces a lawsuit after admitting previously filed financial statements should no longer be relied upon due to improper revenue accounting.

2GeneDx is facing a class action following a 49% stock drop triggered by a 94% write-off related to its Fabric Genomics acquisition.

3PicS N.V. faces a class action regarding alleged IPO omissions concerning its credit procedures and quality.

Amid intensifying legal scrutiny over corporate transparency, Hagens Berman law firm has filed class action lawsuits against Veritone, GeneDx, and PicS N.V. alleging financial misconduct and disclosure failures. According to reports, Veritone admitted its previous financial statements are unreliable due to improper revenue accounting, while GeneDx faces litigation following a 49% stock collapse triggered by a 94% write-off related to its Fabric Genomics acquisition. Additionally, PicS is accused of omitting material information regarding credit procedures and quality in its IPO prospectus.

These legal actions come as technology and genetic testing sectors face mounting pressure, with investors seeking to recover losses linked to alleged market misinformation. Looking at peer performance, AI and biotech firms have experienced sharp volatility recently; for instance, similar diagnostic firms have seen varied declines during asset re-evaluation cycles per market data. Legal experts note that Veritone's admission of accounting errors places it at higher specific risk compared to cases solely based on stock price fluctuations.

Traders should monitor liquidity and price volatility for these instruments in upcoming sessions as the market digests these legal developments. According to the economic calendar, investors are awaiting a speech by ECB's Lagarde and Eurozone GDP data on June 5, 2026. These macro catalysts could further impact global market sentiment and capital flows into companies currently embroiled in litigation.